Cart
sales@molnova.com
PF-06952229
CAS No. 1801333-55-0
PF-06952229( PF06952229 )
Catalog No. M26371 CAS No. 1801333-55-0
PF-06952229 is an selective and orally active inhibitor of TGFbR1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 260 | Get Quote |
|
| 10MG | 447 | Get Quote |
|
| 25MG | 714 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | 1368 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | 2673 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF-06952229
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-06952229 is an selective and orally active inhibitor of TGFbR1.
-
DescriptionPF-06952229 is an selective and orally active inhibitor of TGFbR1.(In Vivo):In MCF-7 ER+ HER2-xenograft breast cancer tumor model, PF-06952229 (30 mg/kg; gavage) combines with Palbociclib results in an improved inhibition of pSMAD2 and a significant increase in survival.
-
In Vitro——
-
In VivoPF-06952229 (oral gavage; 30 mg/kg; twice daily; 21 days) combines with Palbociclib 21 days results in an improved inhibition of pSMAD2 in the MCF7 ER+?xenograft breast cancer tumor model. This combination also leads to a significant increase in survival relative to PF-06952229 monotherapy. Animal Model:MCF-7 ER+?HER2-xenograft breast cancer tumor modelDosage:30 mg/kg Administration:Oral gavage; twice daily; 44 days Result:Resulted in an increase in tumor growth inhibition when combined with Palbociclib.
-
SynonymsPF06952229
-
PathwayOthers
-
TargetOther Targets
-
RecptorMRP4| OAT1| OAT3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1801333-55-0
-
Formula Weight458.92
-
Molecular FormulaC23H24ClFN4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (108.95 mM)
-
SMILESCC(C)c1cnc(cc1Nc1ccncc1C(=O)NC(CO)CO)-c1cc(Cl)ccc1F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Simvastatin Hydroxy ...
Simvastatin hydroxy acid (Tenivastatin) sodium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin hydroxy acid sodium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin hydroxy acid sodium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.
-
BI-0474
BI-0474 is a potent KRASG12C inhibitor that inhibits GDP-KRAS::SOS1 protein-protein interactions with an IC50 value of 7.0 nM.BI-0474 exhibits significant antiproliferative activity against NCI-H358 cells harboring the G12C mutation, and shows significant anti-tumor activity in a non-small cell lung cancer xenograft model.
-
Secretin (28-54), hu...
Secretin (28-54), human TFA is a 27-amino acid peptide that works on the human Secretin receptor.
